Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E P Harrigan

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Neurophysiology|January 1, 1978
Segmental reflexes mediated by joint afferent neurons in cat kneeP Grigg, E P Harrigan, K E Fogarty
Archives of Neurology|March 1, 1984
Transverse myelitis due to meningovascular syphilisE P Harrigan, T J McLaughlin, R G Feldman
Journal of Clinical Psychopharmacology|February 24, 2001
Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studiesP E Keck, K R Reeves, E P Harrigan, et al.
Journal of Psychiatric Research|January 5, 2002
Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patientsR H Swift, E P Harrigan, J C Cappelleri, et al.
The Journal of Clinical Psychiatry|March 10, 2001
Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patientsM D Lesem, J M Zajecka, R H Swift, et al.
Psychopharmacology|June 13, 2001
Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trialD G Daniel, S G Potkin, K R Reeves, et al.
Progress in Cardiovascular Diseases|March 28, 2001
The QT intervalM M Bednar, E P Harrigan, R J Anziano, et al.
Psychopharmacology|December 22, 1998
Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trialP Keck, A Buffenstein, J Ferguson, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 8, 1999
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study GroupD G Daniel, D L Zimbroff, S G Potkin, et al.
Psychiatry Research|April 20, 2001
Estimating the consequences of anti-psychotic induced weight gain on health and mortality rateK R Fontaine, M Heo, E P Harrigan, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Neurophysiology|January 1, 1978
Segmental reflexes mediated by joint afferent neurons in cat kneeP Grigg, E P Harrigan, K E Fogarty
Archives of Neurology|March 1, 1984
Transverse myelitis due to meningovascular syphilisE P Harrigan, T J McLaughlin, R G Feldman
Journal of Clinical Psychopharmacology|February 24, 2001
Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studiesP E Keck, K R Reeves, E P Harrigan, et al.
Journal of Psychiatric Research|January 5, 2002
Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patientsR H Swift, E P Harrigan, J C Cappelleri, et al.
The Journal of Clinical Psychiatry|March 10, 2001
Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patientsM D Lesem, J M Zajecka, R H Swift, et al.
Psychopharmacology|June 13, 2001
Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trialD G Daniel, S G Potkin, K R Reeves, et al.
Progress in Cardiovascular Diseases|March 28, 2001
The QT intervalM M Bednar, E P Harrigan, R J Anziano, et al.
Psychopharmacology|December 22, 1998
Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trialP Keck, A Buffenstein, J Ferguson, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 8, 1999
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study GroupD G Daniel, D L Zimbroff, S G Potkin, et al.
Psychiatry Research|April 20, 2001
Estimating the consequences of anti-psychotic induced weight gain on health and mortality rateK R Fontaine, M Heo, E P Harrigan, et al.
Pageof 1